nach oben

Erschienen in:

01.09.2014 | Research Article

Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma

verfasst von: Rahul Bhagat, Sandeep Sriram Kumar, Shilpa Vaderhobli, Chennagiri S. Premalata, Venkateshaiah Reddihalli Pallavi, Gawari Ramesh, Lakshmi Krishnamoorthy

Erschienen in: Tumor Biology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Silencing of tumor suppressor and tumor-related genes by promoter hypermethylation is one of the major events in ovarian carcinogenesis. In this study, we analyzed aberrant promoter methylation of p16 and RAR-β genes in 134 epithelial ovarian carcinomas (EOCs), 23 low malignant potential (LMP) tumors, 26 benign cystadenomas, and 15 normal ovarian tissues. Methylation was investigated by methylation-specific PCR (MSP), and the results were confirmed by bisulfite DNA sequencing. Relative gene expression of p16 and RAR-β was done using quantitative reverse transcriptase PCR (qRT-PCR) on 51 EOC cases, 9 LMP tumors, and 7 benign cystadenomas with 5 normal ovarian tissues. Aberrant methylation for p16 and RAR-β was present in 43 % (58/134) and 31 % (41/134) in carcinoma cases, 22 % (05/23) and 52 % (12/23) in LMP tumors, and 42 % (11/26) and 69 % (18/26) in benign cystadenomas. No methylation was observed in any of the normal ovarian tissues. The mRNA expression level of p16 and RAR-β was significantly downregulated in EOC and LMP tumors than the corresponding normal tissues whereas the expression level was normal in benign cystadenomas for p16 and slightly reduced for RAR-β. A significant correlation of p16 promoter methylation was observed with reduced gene expression in EOC. For RAR-β, no significant correlation was observed between promoter methylation and gene expression. Our results suggest that epigenetic alterations of p16 and RAR-β have an important role in ovarian carcinogenesis and that mechanism along with methylation plays a significant role in downregulation of RAR-β gene in ovarian cancer.

Nur mit Berechtigung zugänglich

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 1998. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed

Three-year report of population based cancer registries 2009–11: National Cancer Registry Programme (ICMR), Bangalore 2013.

Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371–8.CrossRefPubMed

Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res. 2006;12:2788–94.CrossRefPubMed

Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92.PubMedCentralCrossRefPubMed

Warnecke PM, Bestor TH. Cytosine methylation and human cancer. Curr Opin Oncol. 2000;12:68–73.CrossRefPubMed

Baylin SB, Herman JG. DNA Hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–74.CrossRefPubMed

Liggett Jr WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 1998;16:197–206.

Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436–40.CrossRefPubMed

10.

Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase- 4 inhibitor gene in multiple human cancers. Nature. 1994;368:753–6.CrossRefPubMed

11.

Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–7.CrossRefPubMed

12.

Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci. 1992;17:312–5.CrossRefPubMed

13.

Sherr CJ, Roberts JM. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12.CrossRefPubMed

14.

Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell. 1999;97:53–61.CrossRefPubMed

15.

Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res. 2001;264:42–55.CrossRefPubMed

16.

Grummer MA, Thet LA, Zachman RD. Expression of retinoic acid receptor genes in fetal and newborn rat lung. Pediatr Pulmonol. 1994;17:234–8.CrossRefPubMed

17.

Mendelsohn C, Lohnes D, Decrimo D, Lufkin T, LeMeur M, Chambon P, et al. Function of the retinoic acid receptors (RARs) during development (II). Multiple abnormalities at various stages of organogenesis in RAR double mutants. Development. 1994;120:2749–71.PubMed

18.

Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996;10:940–54.PubMed

19.

Yang Q, Mori I, Shan L, Nakamura M, Nakamura Y, Utsunomiya H, et al. Biallelic inactivation of retinoic acid receptor 2 gene by epigenetic change in breast cancer. Am J Pathol. 2001;158:299–303.PubMedCentralCrossRefPubMed

20.

Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, et al. Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer. 2002;2:4 (e1).PubMedCentralCrossRefPubMed

21.

Yang Q, Yoshimura G, Mori I, Sakurai T, Kakudo K. Chromosome 3p and breast cancer. J Hum Genet. 2002;47:453–9.CrossRefPubMed

22.

Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, et al. The role of epigenetic modifications in retinoic acid receptor Beta2 gene expression in human prostate cancers. Lab Investig. 2001;81:1049–57.CrossRefPubMed

23.

Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003;107:970–5.CrossRefPubMed

24.

Jerónimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D, et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res. 2004;10:4010–4.CrossRefPubMed

25.

Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer. 2006;54:109–16.CrossRefPubMed

26.

He M, Vanaja DK, Karnes RJ, Young CY. Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells. Prostate. 2009;69:1643–50.CrossRefPubMed

27.

Björklund P, Akerström G, Westin G. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab. 2007;92:338–44.CrossRefPubMed

28.

Bhagat R, Shilpa V, Premalata CS, Ramesh G, Ramesh C, Pallavi VR, et al. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cell Oncol. 2012;35:473–9.CrossRef

29.

Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–6.PubMedCentralCrossRefPubMed

30.

Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006;8:209–17.PubMedCentralCrossRefPubMed

31.

Parrish RR, Day JJ, Lubin FD. Direct bisulfite sequencing for examination of DNA methylation with gene and nucleotide resolution from brain tissues. Curr Protoc Neurosci. 2012 July; CHAPTER: Unit 7.24. doi:10.1002/0471142301.ns0724s60.

32.

Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med. 2003;349:2042–54.CrossRefPubMed

33.

Milde-Langosch K, Ocon E, Becker G, Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hypermethylation or mutation in endometrioid and mucinous tumors. Int J Cancer. 1998;79:61–5.CrossRefPubMed

34.

McCluskey LL, Chen C, Delgadillo E, Felix JC, Muderspach LI, Debeau L. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol. 1999;72:87–92.CrossRefPubMed

35.

Wong YF, Chung TK, Cheung TH, Nobori T, Yu AL, Yu J, et al. Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett. 1999;136:231–5.CrossRefPubMed

36.

Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, et al. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res. 2006;12:3329–36.CrossRefPubMed

37.

Li M, Huang ZJ, Dong WH, Li XY, Wang XY, He XH, et al. Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism. Zhonghua Fu Chan Ke Za Zhi. 2006;41:408–12.PubMed

38.

Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006;107:299–308.CrossRefPubMed

39.

Leal Rojas P, Anabalón Rodríguez L, García Muñoz P, Tapia Escalona O, Guzmán González P, Araya Orostica JC, et al. Promoter hypermethylation gene patterns in gynecological tumors. Med Clin (Barc). 2009;132:371–6.CrossRef

40.

Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res. 2005;11:5365–9.CrossRefPubMed

41.

Bammidi LS, Neerukonda GN, Murthy S, Kanapuram RD. p16 gene alterations in human ovarian cancer: comparison between tissue and blood samples. Int J Gynecol Cancer. 2012;22(4):553–60.CrossRefPubMed

42.

Widschwendter M, Berger J, Hermann M, Müller HM, Amberger A, Zeschnigk M, et al. Methylation and silencing of retinoic acid receptor-beta 2 gene in breast cancer. J Natl Cancer Inst. 2000;92(10):826–32.CrossRefPubMed

43.

Gao YP, Li M, Zhang YY, Wang H, He XH, Wang ZH. Relationship between RAR-beta gene expression defect and its methylation. Zhonghua Fu Chan Ke Za Zhi. 2007;42(7):472–6.PubMed

44.

Tang D, Kryvenko ON, Mitrache N, Do KC, Jankowski M, Chitale DA, et al. Methylation of RAR-β gene increases prostate cancer risk in black Americans. J Urol. 2013;190(1):317–24.PubMedCentralCrossRefPubMed

45.

Chmelarova M, Krepinska E, Spacek J, Laco J, Nekvindova J, Palicka V. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA. Folia Biol (Praha). 2012;58:246–50.

46.

Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N. Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med. 2012;4(6):1092–6.PubMedCentralPubMed

47.

Khodyrev DS, Loginov VI, Pronina IV, Kazubskaya TP, Garkavtsera RF, Braga EA. Methylation of promoter region of RAR-β2 gene in renal cell, breast and ovarian carcinomas. Russ J Genet. 2008;44(8):983–8.CrossRef

48.

Katsaros D, Cho W, Singal R, Fracchioli S, Rigault De La Longrais IA, Arisio R, et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol. 2004;94:685–92.CrossRefPubMed

49.

Leu YW, Rahmatpanah F, Shi H, Wei SH, Liu JC, Yan PS, et al. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 2003;63:6110–5.PubMed

50.

Marchini S, Codegoni AM, Bonazzi C, Chiari S, Broggini M. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer. 1997;76:146–9.PubMedCentralCrossRefPubMed

51.

Fujita M, Enomoto T, Haba T, Nakashima R, Sasaki M, Yoshino K, et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer. 1997;74:148–55.CrossRefPubMed

52.

Niederacher D, Yan HY, An HX, Bender HG, Beckmann MW. CDKN2A gene inactivation in epithelial sporadic ovarian cancer. Br J Cancer. 1999;80:1920–6.PubMedCentralCrossRefPubMed

53.

Kaiser PC, Körner M, Kappeler A, Aebi S. Retinoid receptors in ovarian cancer: expression and prognosis. Ann Oncol. 2005;16(9):1477–87.CrossRefPubMed

Titel: Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma
verfasst von: Rahul Bhagat
Sandeep Sriram Kumar
Shilpa Vaderhobli
Chennagiri S. Premalata
Venkateshaiah Reddihalli Pallavi
Gawari Ramesh
Lakshmi Krishnamoorthy
Publikationsdatum: 01.09.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 9/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2136-1

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma

Abstract

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas

ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells

Regulation of metastasis of pediatric multiple myeloma by MMP13

Aberrant promoter methylation of p15 INK4b and p16 INK4a genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis

Prognosis value of mitotic kinase Aurora-A for primary duodenal adenocarcinoma

Role of IL-17F T7488C polymorphism in carcinogenesis: a meta-analysis

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie